MURA Stock Overview
A clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mural Oncology plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.22 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$2.87 |
| Beta | 0 |
| 1 Month Change | -21.27% |
| 3 Month Change | -4.17% |
| 1 Year Change | -43.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.26% |
Recent News & Updates
Recent updates
Here's Why We're Watching Mural Oncology's (NASDAQ:MURA) Cash Burn Situation
Nov 26
Here's Why We're A Bit Worried About Mural Oncology's (NASDAQ:MURA) Cash Burn Situation
Jul 17We're Keeping An Eye On Mural Oncology's (NASDAQ:MURA) Cash Burn Rate
Mar 28Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value
Mar 04Shareholder Returns
| MURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | -2.3% | -2.6% |
| 1Y | -43.2% | -6.3% | 24.5% |
Return vs Industry: MURA underperformed the US Biotechs industry which returned -6.2% over the past year.
Return vs Market: MURA underperformed the US Market which returned 23.1% over the past year.
Price Volatility
| MURA volatility | |
|---|---|
| MURA Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MURA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MURA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 109 | Caroline Loew | www.muraloncology.com |
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors.
Mural Oncology plc Fundamentals Summary
| MURA fundamental statistics | |
|---|---|
| Market cap | US$55.00m |
| Earnings (TTM) | -US$153.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs MURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$153.78m |
| Earnings | -US$153.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:04 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mural Oncology plc is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andres Maldonado | H.C. Wainwright & Co. |
| Judah Frommer | Morgan Stanley |
| Laura Prendergast | Raymond James & Associates |